Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs ONO 8577 (Primary) ; Mirabegron; Solifenacin
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 25 Sep 2017 Planned End Date changed from 1 Mar 2018 to 1 Oct 2017.
- 25 Sep 2017 Status changed from not yet recruiting to recruiting.
- 13 Apr 2017 New trial record